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ARTICLE
Cholesteryl α-D-glucoside 6-acyltransferase
enhances the adhesion of Helicobacter
pylori to gastric epithelium
Hau-Ming Jan1, Yi-Chi Chen 1,2, Tsai-Chen Yang1, Lih-Lih Ong1,3,4, Chia-Chen Chang3,
Sasikala Muthusamy1,5,6, Andualem Bahiru Abera1,5,6, Ming-Shiang Wu7, Jacquelyn Gervay-Hague 8,
Kwok-Kong Tony Mong3,9✉ & Chun-Hung Lin 1,2,9✉
Helicobacter pylori, the most common etiologic agent of gastric diseases including gastric
cancer, is auxotrophic for cholesterol and has to hijack it from gastric epithelia. Upon uptake,
the bacteria convert cholesterol to cholesteryl 6′-O-acyl-α-D-glucopyranoside (CAG) to
promote lipid raft clustering in the host cell membranes. However, how CAG appears in the
host to exert the pathogenesis still remains ambiguous. Herein we identified hp0499 to be the
gene of cholesteryl α-D-glucopyranoside acyltransferase (CGAT). Together with cholesteryl
glucosyltransferase (catalyzing the prior step), CGAT is secreted via outer membrane vesi-
cles to the host cells for direct synthesis of CAG. This significantly enhances lipid rafts
clustering, gathers adhesion molecules (including Lewis antigens and integrins α5, β1), and
promotes more bacterial adhesion. Furthermore, the clinically used drug amiodarone was
shown as a potent inhibitor of CGAT to effectively reduce the bacterial adhesion, indicating
that CGAT is a potential target of therapeutic intervention.
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H elicobacter pylori infects more than half of the world’spopulation1. The bacterial infection not only results invarious gastrointestinal diseases that include gastric
carcinoma and gastric mucosa-associated lymphoid tissue lym-
phoma, but also represents a leading cause of cancer-related
deaths2. The pathogenicity of H. pylori is closely associated with
the genes of cag-pathogenicity island, the 40-kb-long sequence
of 31 coding regions including the type IV secretion system
(T4SS)3,4. Following the attachment of H. pylori to gastric epi-
thelial cells, the T4SS apparatus injects the cag-pathogenicity
island-encoded protein CagA into the attached host cells. Once
delivered inside the cells, CagA undergoes tyrosine phosphor-
ylation by c-Src family kinases. The phosphorylated CagA then
activates several cellular signaling processes, including those
leading to cancer development5.
The attachment of H. pylori to gastric epithelia is a necessary
process for colonization, as well as an initial step in the patho-
genesis6. The increasing level of H. pylori adhesion was found
relevant to several deteriorating developments, such as epithelial
cell degeneration and mucin depletion. Among several important
factors contributing to the bacterial adhesion, BabA is the best
characterized adhesin that recognizes Lewisb/ABO blood group
antigens7,8. Another adhesin SabA binds specifically to sialyl
Lewisx and sialyl Lewisa antigens9. The T4SS pili of H. pylori,
probably assembled upon an initial contact with host cells10, are
known to interact with the integrins α5 and β1 to enhance the
adherence11,12. Furthermore, the bacterium produces cholesteryl
α-glucoside derivatives to affect the bacterial adhesion13.
H. pylori is auxotrophic for cholesterol. It assimilates choles-
terol into its membrane by taking up cholesterol from epithelial
cells of the stomach. Upon uptake, the bacterial cells modify the
cholesterol by α-glucosylation. Specifically, the glucosyltransferase
encoded by hp0421 catalyzes the transfer of glucose to the 3-
hydroxyl group of cholesterol, yielding cholesteryl α-D-gluco-
pyranoside (CG). There is a subsequent modification occurring at
O6′ of glucose in CG, i.e., cholesteryl 6′-O-acyl-α-D-glucopyr-
anoside (CAG) or cholesteryl 6′-O-phosphatidyl-α-D-glucopyr-
anoside are made by attaching an acyl or phosphatidyl group,
respectively. We previously developed a metabolite-tagging
method for characterizing these derivatives with a femto-molar
detection limit14. The subsequent analysis led to the findings that
these bacteria acquire phospholipids from the membrane of
epithelial cells for CAG biosynthesis. The increase in longer CAG
acyl chains helped to promote lipid raft clustering in the host cell
membranes and thus the delivery of virulence factor CagA into
the host cell14.
Herein we report the identification of hp0499 as the gene of
cholesteryl α-D-glucopyranoside 6′-acyltransferase (CGAT), as
well as characterization of the corresponding recombinant pro-
tein. The enzyme is located in the outer membrane of H. pylori,
secreted extracellularly in the form of outer membrane vesicles
(OMVs), and thus delivered to the host cells to directly produce
CAGs there for the lipid raft-mediated enhancement of H. pylori
adhesion. Additionally, a potent CGAT inhibitor was discovered
to effectively blockade the H. pylori adhesion, demonstrating
CGAT to be a potential target of therapeutic intervention.
Results
Acyl chain length of CAG affects bacterial adhesion. Figure 1a
shows the biosynthetic pathway of cholesterol-α-glucosides. Upon
uptake of cholesterol, H. pylori employs cholesterol glucosyl-
transferase (CGT) to convert cholesterol to CG, followed by the
reaction of CGAT to catalyze the acyltransfer to produce CAG.
We previously demonstrated that CAG, rather than CG or cho-
lesteryl 6′-O-phosphatidyl-α-D-glucopyranoside, was able to
promote lipid rafts clustering in the host cell membranes, as well
as CagA translocation and phosphorylation14. Wang et al.13
reported that the loss of cholesteryl-α-glucoside derivatives
abolished the adhesion of H. pylori to AGS cells13. Both studies
provide the impetus to understand if CAG is the key to regulate
the bacterial adhesion. Among CG and CAGs of different chain
length (such as CAG(14:0), CAG(16:0), CAG(18:0), and CAG
(18:1)) added to the culture of AGS cells, CAG(18:0) enhanced
the lipid rafts clustering to the highest degree when ganglioside
GM1 was utilized to label the formation of lipid rafts (Fig. 1b).
Furthermore, AGS cells were treated with each of these CG and
CAGs, infected with H. pylori 26695 and then examined for the
extent of adhesion by flow cytometry. The result was consistent
with that obtained from the lipid rafts study, i.e., the longer the
acyl chain was, the higher levels there were in the bacterial
adhesion (Fig. 1c, d), CagA translocation, and the corresponding
tyrosine phosphorylation (Fig. 1e). Interestingly, these studies
were not favored by unsaturation in the acyl chain, suggesting
that the membrane fluidity or packing in the lipid chains appears
to be critical.
Identification and characterization of H. pylori CGAT. Pre-
viously phospholipids were shown to serve as the precursors for
the biosynthesis of CAG and cholesteryl 6′-O-phosphatidyl-α-D-
glucopyranoside14. In an attempt of identifying the enzyme to
catalyze the formation of CAGs, we performed several gene-
knockout strains related to phospholipase, esterase, or acyl-
transferase (see Methods section for the list of candidates) by
inserting a kanamycin-resistance cassette into desirable genes of
H. pylori 26695. Among these gene-knockout strains, only
Δhp0499 did not produce a detectable level of CAGs, suggesting
that the Δhp0499 strain is a CGAT-deficient strain (ΔCGAT)
(Supplementary Fig. 1a). We additionally prepared the CGAT-
knock-in strain by inserting the intact hp0499 gene with a
chloramphenicol-resistance cassette to the genome upstream of
the aforementioned hp0499-modified sequence. The CGAT-
knock-in strain indeed restored the capability of synthesizing
CAG (Supplementary Fig. 1a). Both data confirmed that hp0499
is the gene responsible for CAG production.
Two recombinant forms of CGAT were overexpressed in
Escherichia coli, including one containing an N-terminal 6x His
tag and the other having an N-terminal maltose-binding protein
(MBP-CGAT). Despite several problems initially encountered,
such as low expression level, formation of inclusion bodies and
protein instability, we finally overcame these difficulties after
numerous trials and errors. MBP-CGAT displayed fourfold
higher activity than the other His-tagged CGAT (Supplementary
Fig. 1b) by using LC-MS analysis to measure CAG(14:0) that
resulted from the enzymatic reaction of CG and 1,2-dimyristoyl-
sn-glycero-3-phosphatidylethanolamine (PE(14:0,14:0)). As a
consequence, only MBP-CGAT (hereafter called CGAT) was
characterized in the following studies. The enzyme has two
substrates, namely phosphatidylethanolamine (PE) as the acyl
donor and CG as the acceptor. Since PE contains two acyl chains,
we thus utilized PE(d16:0/18:1) (i.e., deuterium-labeled palmitic
acid (16: 0) and unlabeled oleic acid (18:1) at a1- and a2-positions
of the glycerol moiety, respectively) to identify which acyl
chain in the PE was hydrolyzed and transferred to CG. The
resulting analysis indicated that CGAT belongs to the family of
phospholipase A1 to catalyze the formation of CAG(d16:0) and
1-hydroxy-2-oleoyl-sn-glycero-3-phosphoethanolamine (lyso-PE
(18:1)), as shown in Supplementary Fig. 1c, d, respectively.
Furthermore, CGAT was active in the range of pH 3.5–9.0 with
an optimum activity at pH 4.5 (Supplementary Fig. 1e).
Lineweaver–Burk plot analysis of CGAT steady-state kinetics
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indicated that the catalysis operates through a sequential rapid-
equilibrium random bi-bi mechanism (Supplementary Fig. 1f, g).
The values of KCG and KPE were 26.0 and 290 μM, respectively, and
the turnover number was close to one per sec (kcat= 58.5min−1).
Meanwhile, we also examined the metal ion dependence and
substrate specificity on phospholipids. Among seven divalent
metal ions, the enzyme became the most active in the presence of
calcium ion (Supplementary Fig. 1h). CGAT displayed broad
specificity for several lipids (Supplementary Fig. 1i, j); in
particular, a phosphatidyl moiety is required for the recognition.
Acceptable substrates need to have two acyl chains (see the rate
difference between PE vs. 1-myristoyl-2-hydroxy-sn-glycero-3-
phosphoethanolamine (2-lyso-PE) although they both can be
saturated (Supplementary Fig. 1i) or the one at a2-position is
unsaturated (Supplementary Fig. 1j). Obviously, CGAT mainly
preferred PE (100% relative activity), phosphatidylserine (PS,
~25–50% activity depending on the lipid compositions) and
phosphatidylcholine (PC, ~4–17% activity). In consistence with
the previous result that CAGs of varied chain length existed in the
co-culturing of AGS cells with H. pylori, CGAT accepted all the
five phosphatidylcholines of different chain lengths (Supplemen-
tary Fig. 1k). We did not examined PEs simply because most PEs
are rarely soluble in the assay buffer (100 mM sodium formate,
25 mM CaCl2, pH 4.5).
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Fig. 1 CAGs of varied chain length were able to enhance H. pylori adhesion and the corresponding CagA translocation. a Biosynthetic pathway of CAG in
all H. pylori strains where cholesterol α-glucosyltransferase (CGT) and cholesteryl α-D-glucoside acyltransferase (CGAT) consecutively catalyze the
reactions to yield cholesteryl α-D-glucopyranoside (CG) and CAG, respectively. The R group of CAG represents O6′-esters of different fatty acids, e.g.,
myristic acid (14:0), palmitic acid (16:0), stearic acid (18:0), and oleic acid (18:1). b Representative confocal images of lipid rafts clustering in the presence
of CG or CAGs with different acyl chain. After AGS cells were treated with CG or CAG (as indicated) for 1 h, the lipid rafts (GM1) were then labeled with
Alexa Fluor 594-conjugated cholera toxin subunit b (red fluorescence). Confocal images were collected under a Leica SP5 X inverted confocal microscope.
Scale bar: 5 μm. c, d Degree of H. pylori adherence to AGS cells is dependent on the acyl chain of CAG. AGS cells were first treated with CG or CAGs (as
indicated) for 1 h, infected with H. pylori strain 26695 for another 1 h, and then subjected to flow cytometry analysis. Adherence was measured as the
proportion of adhered AGS cells with H. pylori (%; shown in each plot). The resulting quantitation of cell adherence was normalized in comparison with the
control and shown in d. Data are shown as mean ± SD (standard deviation). All statistically significant differences are indicated with asterisks; **p < 0.01,
*p < 0.05 vs. the control (n= 3). e Effects of CAGs with different acyl chains on CagA translocation and CagA tyrosine phosphorylation that was detected
by immunoblotting after the co-culture of AGS cells with H. pylori 26695 as described in (c). Data sources for d are provided in Supplementary Data 1.
Uncropped immunoblot images for e are provided in Supplementary Fig. 4.
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Cellular locations of CGAT. To study the cellular location of
CGAT, the cells of H. pylori 26695 were cultured, lysed, and
then extracted by N-lauroylsarcosine and n-dodecyl-β-D-mal-
topyranoside to obtain the fractions of cytosol, inner and outer
membranes15. Enzyme activity assay was conducted to determine
where CGAT is localized. The enzyme was found to exist mainly
in the outer membrane, but not in the other locations (Fig. 2a),
which is coherent to the proposed idea by Scott et al.16 that most
H. pylori surface proteins have high values of isoelectric point to
likely resist the acidic environment. The isoelectric point of
CGAT is 9.26. Moreover, the CGAT activity was observed in the
OMVs, rather than in the culture medium (Fig. 2b), suggesting
that CGAT resided in the outer membrane can be enclosed in the
OMVs and secreted to the extracellular space. Figure 2c showed
the direct evidence from cryo-transmission electron microscopy
that CGAT was present in the OMVs isolated from the strains of
H. pylori 26695, ΔCGT-knock-out, and CGAT-knock-in, instead of
ΔCGAT-knock-out. When these OMVs were isolated from
hp0499-containing strains and then surveyed for proteomic ana-
lysis, CGAT was shown among a range of 310–420 proteins
identified (Supplementary Table 1). Further activity analysis of
these OMVs (Fig. 2d, e) concluded that H. pylori OMVs contained
the two enzymes CGT and CGAT. As shown by confocal fluor-
escence microscopy (Fig. 2f, g, Supplementary Movie 1), CGAT
was translocated to AGS cells after the cells had been pretreated
with H. pylori 26695 OMVs or infected by H. pylori 26695.
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Fig. 2 Cellular location of CGAT. a, b Cellular location of CGAT was determined by the enzyme activity. a IM and OM stand for the abbreviations of inner
and outer membranes, respectively. See Methods section for the procedure to obtain the fractions of cytosol, IM, and OM of H. pylori 26695. b The three
fractions were obtained from the same cell number of H. pylori 26695. These fractions were individually incubated for 2 h with the mixture of CG and PE at
pH 4.5. The resulting CAG products were analyzed by LC-MS analysis. Data were obtained from three replicates. Data are shown as mean ± SD. c CGAT
existing in OMVs was identified by cryo-transmission electron microscopy. OMVs were purified from different H. pylori strains and examined if they
contained CGAT that is labeled by immune-gold (shown in black dots and indicated by white arrows). Scale bar: 50 nm. d, e Levels of CGT (d) and CGAT
(e) activities in the OMVs that were purified from different H. pylori strains and determined by LC-MS analysis. Data are shown as mean ± SD. f CGAT was
shown in the co-culture of AGS cells with different H. pylori strains. After co-culture with H. pylori for 8 h, the cells were fixed and stained with CGAT-
specific antibody (Alexa Fluor 488, green). Nuclei were counterstained with DAPI (blue). Lower panels showed the magnified images from a part of upper
panels. Scale bars denoted 20 (upper) and 5 (lower) μm. g CGAT was shown in the AGS cells with a prior treatment with or without H. pylori 26695 OMV,
ΔCGAT OMV, or CGAT-knock-in OMV for 8 h. The cells were then stained as described in (f). Scale bars denote 20 (upper) and 5 (lower) μm. Data
sources for a, b, d, and e are provided in Supplementary Data 1.
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CGAT is delivered to host cell to enhance H. pylori adhesion. It
is known that CAG(14:0) and CAG(19c:0) mainly exist in H.
pylori, as the reaction products of CGAT. To understand how the
translocated CGAT possibly functions in the host cell, the pri-
mary concern is to analyze the CGAT products once the enzyme
becomes available in the host cells. We treated AGS cells with
recombinant proteins CGT and CGAT both to mimic the
circumstances of bacterial infection. There was a significant
change in the CAG compositions (Fig. 3a), i.e., most CAGs
contain longer fatty acid chains, including (16:0), (18:0), and
(18:1), after the treatment of AGS cells with both CGT and
CGAT. Apparently the translocated CGAT accepted available PEs
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Fig. 3 Enhanced levels in lipid rafts clustering, adhesion, and CagA translocation by the concerted actions of CGAT and CGT. a, b The compositions of
CAGs in AGS cells after the cells were treated with both recombinant CGT and CGAT (a), or with the OMVs of H. pylori 26695 (b). c Enhanced level of
lipid raft clustering was observed after AGS cells were treated with both recombinant CGT and CGAT for 8 h. Red fluorescence denotes the lipid rafts.
Scale bar: 20 μm. d, e Time- and does-dependent confocal images of lipid raft clustering in AGS cells. d The images were obtained after the cells were
treated with the purified OMVs (200 μg) from different H. pylori strains at 1, 2, 6, and 8 h. e The images were generated after the cells were treated with
H. pylori 26695 OMVs for 8 h. Red fluorescence denotes the lipid rafts. Scale bar: 20 μm. f, h Enhanced H. pylori adherence to AGS cells after the cells were
incubated with recombinant CGT or/and CGAT (f) or with the purified OMVs from different H. pylori strains (h). AGS cells were treated with the enzymes
or OMVs for 8 h and then infected with H. pylori 26695 for another 1 h. Adherence was examined by flow cytometry analysis and shown as the proportion
of adhered cells with H. pylori (%; shown in each plot). g, i Quantitation of the adhered cells of f and h was normalized in comparison with the negative
control, respectively. All statistically significant differences are indicated with asterisks; **p < 0.01, *p < 0.05 vs. control group (n= 3). j, k Immunobloting
analysis on CagA translocation and the related tyrosine phosphorylation to examine the effect of recombinant enzymes (j) or purified OMVs (k). The
procedure was similar to that of f and h. The uncropped images are provided in Supplementary Fig. 4. In a, b, g and i, data are shown as mean ± SD and the
data sources are provided in Supplementary Data 1.
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or phosphatidylserines in AGS cells. Likewise, the treatment with
H. pylori 26696 OMVs also resulted in a similar profile (Fig. 3b).
In agreement with the aforementioned observation that CGT and
CGAT were delivered to the host cells by the OMVs (Fig. 2f, g),
Fig. 3b indicated that the two enzymes, once delivered to the host
cells, became functional to synthesize CAGs of longer acyl chains.
The result is coherent to the previous report14 that the co-culture
of H. pylori with AGS cells generated a significant amount of
CAGs containing longer or/and unsaturated acyl chains.
The aforementioned enzyme or OMV treatment also enhanced
the degree of lipid rafts clustering in a time- (Fig. 3c, d) and dose-
dependent manner (Fig. 3e). Furthermore, we had two observa-
tions to corroborate the indispensable production of CAGs. There
was no enhancement of lipid rafts clustering if only CGT or
CGAT was present in the study. Lipid rafts clustering only
became evident in the regions to which H. pylori 26695 OMVs
were attached, as shown by the real-time imaging (Supplementary
Movie 1), in contrast to those without the OMV attachment.
Additional examinations on the effect of H. pylori adhesion also
showed the consistent trend, such as flow cytometry analysis
(Fig. 3f–i), cagA translocation, and the corresponding tyrosine
phosphorylation (Fig. 3j, k). Taken together, these results
indicated that the presence of both CGT and CAGT in the host
cells is the prerequisite for the enhancement of lipid raft
clustering, bacterial adhesion, and the subsequent virulence.
CAGs help to gather adhesion molecules. Although lipid rafts
clustering and the chemoattraction of cholesterol17 is a driving
force for H. pylori to move toward the rafts region, leading to
the enhancement of bacterial adhesion, the detailed mechanism
still remains unclear. It was reported that integrins α5 and β1
were recruited to the raft region when lipid rafts were clustered
in T cells18,19. Both integrins were shown in gastric epithelial
cells to interact with T4SS of H. pylori to enhance the bacterial
adhesion11. To examine a possible correlation of the integrins
with the CAG-induced clustering of lipid rafts, we first found
that integrins α5 and β1 were both co-localized with CAG-
induced lipid rafts in AGS cells (Fig. 4a). H. pylori 26695
OMVs, rather than those containing CGT or CGAT only, were
able to recruit integrin β1 to the raft regions in AGS and KATO
III cells (Fig. 4b and Supplementary Fig. 2, respectively).
Despite enhanced H. pylori adhesion to AGS cells in the pre-
sence of CAG(18:0), the adherence and the subsequent CagA
translocation were inhibited by integrin α5- or β1-blocking
antibodies (Fig. 4c–e).
Like the integrins, Lewisb and sialyl Lewisx antigens were able
to congregate in the rafts region induced by the treatment of H.
pylori 26695 OMVs in KATO III cells (that were used instead of
AGS cells because the latter cells have extremely low expression of
Lewis antigens, including Lewisb and sialyl Lewisx). Figure 4f, h
displayed the co-localization of the lipid rafts and Lewisb.
Overlapped staining of the lipid rafts and sialyl Lewisx was
shown in Fig. 4g, i. Again in these figures, H. pylori 26695 OMVs
produced higher co-localization signals than the OMVs isolated
from the knockout strains. Likewise, the use of Lewisb- or integrin
β1-blocking antibodies also significantly blockaded H. pylori
adhesion to KATO III cells in the presence of CAG(18:0), as
shown in Fig. 4j, k. These results suggested that CAG-induced
clustering of lipid rafts gathered bacterial adhesion-related
molecules in the raft regions, such as the integrins, Lewisb, and
sialyl Lewisx, resulting in the enhancement of bacterial adhesion.
Amiodarone is a CGAT inhibitor to prevent H. pylori adhesion.
To study if the enzyme is a target of therapeutic intervention,
we screened a number of molecules with the activity assay of
CGAT and then identified amiodarone to be a potent inhibitor
(IC50= 13.8 μM, Fig. 5a). The compound was then added to H.
pylori-infected AGS cells for further evaluation. As compared to
the negative control, 50 μM amiodarone significantly reduced
the production of CAG in AGS cells, bacterial adhesion,
CagA translocation, and the related tyrosine phosphorylation
(Fig. 5b–e, respectively). Apparently, inhibiting CGAT activity is
the key to decrease the virulence of H. pylori. In the presence
of OMVs, amiodarone still effectively abolished the adherence of
H. pylori to AGS cells (Fig. 5f, g), as well as the related CagA
translocation (Fig. 5h). Moreover, we also examined if amiodarone
caused any effect other than CGAT inhibition. Before AGS cells
were infected with H. pylori, the AGS cells were incubated with
(or without) amiodarone and the OMVs that had been treated with
CAG(18:0). The result showed no difference in the degree of
bacterial infection, and the related CagA translocation (Fig. 5f–h)
no matter if amiodarone was present. Meanwhile, we also obtained
a similar result in the following study, i.e. no difference in the
presence or absence of amiodarone. H. pylori was treated with
(or without) amiodarone in the presence of CAG(18:0) before the
bacteria infected AGS cells (Supplementary Fig. 3). These results
suggested that amiodarone takes effect only on the CAG-induced
changes via inhibition of CGAT activity.
Furthermore, we examined the CAG levels in ten multiple
drug-resistant (MDR) strains of H. pylori that displayed resistance
to the treatment of levofloxacin, metronidazole, and clarithro-
mycin. Interestingly, their CAG levels were 10–150 times higher
than that of H. pylori 26695 (Fig. 5i). To verify if amiodarone also
inhibits the CGAT activity and the related pathogenesis in these
resistant strains, one strain (5024) producing the highest CAG
level had been incubated with amiodarone before it infected AGS
cells. To our delight, at the concentration of 50 μM, aminodarone
significantly reduced not only the CAG level (Fig. 5j) but also the
bacterial adhesion (Fig. 5k), CagA translocation, and the related
tyrosine phosphorylation (Fig. 5l). These results pave the way for
further development of CGAT inhibitors for the purpose of
therapeutic intervention.
The amiodarone-based anti-adhesion seems to offer an
alternative for antimicrobial therapy. CGAT, the product of
hp0499, was originally proposed to be an outer membrane
phospholipase A that shares 19.7% sequence identity and 35.4%
similarity with E. coli outer membrane phospholipase A. Our
result indicated that CGAT is indeed a phospholipase A1, but the
enzyme additionally catalyzes the acyltransfer to the 6′-OH of
CG, resulting in the formation of CAG. In contrast to most
bacterial infections where bacterial molecules are propagated to
the host cell via passive diffusion or direct cell contact, our result
represents a very distinctive scenario. The two enzymes CGT and
CGAT are packaged in the OMVs and shipped to the host cell
(Fig. 6a). Upon fusion of OMVs with the host cell membranes,
the two enzymes are released to directly utilize the necessary
substrates to form CAGs in the host cell. Moreover, CAG can be
considered as a modified version of cholesterol to modulate the
features of the host membranes, including lipid rafts formation
and clustering. This helps to gather several adhesion molecules
around the rafts region, such as Lewis antigens and integrins α5
and β1 (Fig. 6b). The resulting enhanced interactions thus help H.
pylori to adhere much better (Fig. 6c, Supplementary Movie 2).
As a consequence, our previous14 and current studies thus
demonstrate the intriguing interplay between H. pylori and gastric
epithelial cell. The bacteria not only hijack cholesterol and PE
from the host to make CAG but also leverage the OMVs to
deliver the biosynthetic machinery for the direct and efficient
synthesis in the host cell. This leads to a dramatic change on the
host cell surface; the enhanced lipid rafts clustering further
promotes a higher level of bacterial adhesion.
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-0855-y
6 COMMUNICATIONS BIOLOGY |           (2020) 3:120 | https://doi.org/10.1038/s42003-020-0855-y | www.nature.com/commsbio
Discussion
In this study, we identified CGAT as a steryl glycoside acyl-
transferase. Although this enzyme has been reported to exist in a
number of organisms, there is no gene information available20,21.
The cloning, expression and characterization of CGAT, to the
best of our knowledge not only stands for the first in-depth study
of a steryl glycoside acyltransferase but also provides useful
information to identify enzymes of the same category and
understand their functional roles in other organisms.
In the H. pylori pathogenesis, the proteins of cag-pathogenicity
island are associated with integrins α5 and β1 of epithelial
cells11,22, which induces T4SS assembly and the subsequent
injection of CagA. Given that integrins are generally resided in
the basolateral side of epithelial cells, it is intriguing to know the
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reason why the integrins can interact with the T4SS of H. pylori.
Hecht and co-workers23 found that during the infection of E. coli,
integrin β1 translocated to the apical side of intestinal epithelial
cells after the destruction of tight junction proteins. H. pylori was
shown to impair the tight junction24. The bacteria secreted the
serine protease HtrA to open cell-to-cell junctions through clea-
vage of junctional proteins, such as occludin, claudin-8, and E-
cadherin in polarized epithelial cells. The opening allowed H. pylori
to move into the intercellular space between adjacent cells and
eventually reach to basolateral locations25. As a consequence, it is
intriguing to examine if and how the presence of CAG correlates
with the impairment of tight junction and junctional proteins.
High cholesterol level is known in association with cardio-
vascular diseases (CVDs), such as atherosclerosis26–30. Therefore,
it is intriguing to understand if the cholesterol uptake by H. pylori
correlates with CVDs; especially the link of H. pylori ser-
opositivity to CVD has been described in several reports31–35.
How the infection of H. pylori influences CVD, however, remains
unclear. CAG, considered to be a modified version of cholesterol,
was shown to promote lipid rafts clustering in gastric epithelia in
this and previous studies14. Caveolae, representing cholesterol-
and sphingolipid-enriched invaginations of the plasma mem-
branes, were identified as a potential regulator of vascular dys-
function and heart disease36–39. Moreover, our observation
indicated that CAG is rather stable under cell culture conditions,
implicating that CAG may not be only available in the infected
gastric epithelia, and that their dissemination could promote
caveolin-related lipid rafts clustering and thus lead to vascular
dysfunction and coronary heart disease. Nevertheless, the levels of
CAGs are dynamic depending on the surrounding nutrient
condition, not mentioning that different H. pylori strains were
found to produce various levels of CAGs. This might explain why
there are contradictory observations reporting little or no rele-
vance between H. pylori infection and CVD40–42.
Adherence of H. pylori to the gastric epithelium rendered H.
pylori 100–1000 times more resistant to antibiotics than non-
adherent bacteria43. The enhanced adhesion of H. pylori was
observed in epithelial degeneration and in the presence of mucin
depletion symptoms when the patients suffered from gastritis44.
Several reports demonstrated that the prevention of bacterial
adhesion was able to reduce bacterial survival and virulence45,46;
especially the number of bacteria and the related symptoms were
significantly diminished47–49. Moreover, a recent study showed
that cholesterol-derived glucosides were related to antibiotic
resistance50, which was further supported by the extremely high
levels of CAGs in the MDR strains that were clinically isolated
(Fig. 5i). Since anti-adhesion impedes the binding of bacteria
without affecting microbial viability, little or no pressure is
applied to select between the wild-type bacteria and mutants. An
anti-adhesion therapy thus possibly minimizes the occurrence of
drug resistance. It is extremely difficult, however, to develop
multiple inhibitors to prevent the bindings of all adhesion
molecules given that bacteria usually have several ways to adhere
to the host cells. In this study, the CAG-induced clustering of
lipid rafts appears to be the driving force to intensify the
bacteria–host cell interactions. The development of CGAT inhi-
bitors turns out to be superior to those directly blocking any of
the aforementioned interactions. Intriguingly our result indicated
that the bacterial adhesion became very limited (Fig. 5d, k) once
the CGAT activity was inhibited. Taken together, there are several
advantages associated with CGAT inhibitors, such as inhibition of
bacterial adhesion, reduction of the OMV fusion to the host cell,
and less likely to develop drug resistance. Our discovery of
amiodarone thus becomes valuable because this molecule or other
CGAT inhibitors can be utilized in conjunction with antibiotics,
especially when facing the emerging threat of antibiotic resistance.
Methods
H. pylori strains and bacterial cultures. H. pylori was grown on CDC Anaerobic
Blood Agar plates (Becton Dickinson) under microaerobic (Anaeropack Campylo
System, Mitsubishi Gas Chemical, Tokyo, Japan) conditions at 37 °C for 2 days. For
liquid cultures, H. pylori was grown in Brucella broth (Difco) containing 0.2% β-
cyclodextrin (Sigma), 10% fetal bovine serum, and 1% IsoVitaleX (Becton Dick-
inson) for 60 h. For kanamycin-resistant strain selection, 20 μg ml−1 kanamycin
was used. For chloramphenicol-resistant strain selection, 5 μg ml−1 chlor-
amphenicol was used. The knockout strains were generated from H. pylori 26695
by inserting antibiotic-resistance cassettes into the target genes via homologous
recombination. For knock out of hp0421 (ΔCGT), chloramphenicol-resistance
cassette was used. For knock out of hp0499 (ΔCGAT), hp0420 and hp0935, the
kanamycin-resistance cassette was used. Three genes (hp0420, hp0935, and hp0499)
were selected as the proposed candidates to encode CGAT. hp0420 was related to
acyl carrier protein (ACP)-dehydratase/CoA or thioesterase, while hp0935 was
considered to be an N-acetyltransferase in H. pylori. hp0499 was previously
reported as outer membrane phospholipase A1 in H. pylori. Our data shown in
Supplementary Fig. 1 indicated hp0499 to be CGAT. To complement the CGAT
mutation, a CGAT-knock-in strain was generated from the strain of ΔCGAT by
inserting one intact hp0499 gene with a chloramphenicol-resistance cassette to the
upstream of the mutant hp0499 gene locus described above. The correct trans-
formants were obtained by selection with chloramphenicol and kanamycin and
then verified by PCR. Clinical isolated multiple drug-resistant (MDR) strains,
including 4923, 4974, 5004, 4925, 5033, 4973, 5024, 5022, 4962, and 4955 were
obtained from National Taiwan University Hospital, Taiwan. All these MDR
strains are resistant to clarithromycin, metronidazole, and levofloxacin. The
resistance breakpoints for clarithromycin, metronidazole and levofloxacin were
defined as >0.5, >8, and >1 μg ml−1, respectively51.
Cell lines and cell culture. Mammalian cells were maintained within a humidified
environment and under 5% CO2 at 37 °C. AGS (human gastric epithelial, female)
and KATO III (human neoplastic epithelial, male) cells were maintained in Dul-
becco’s modification of Eagle’s medium (Gibco, Invitrogen) supplemented with
fetal bovine serum (10%; HyClone) and penicillin/streptomycin (1%; Biological
Industries). Both AGS and KATO III cell lines were obtained from the American
Type Culture Collection (ATCC) and were certified by ATCC. ATCC uses mor-
phology-, karyotyping-, and PCR-based approaches to confirm the identity of both
cell lines. Cell lines were tested negative for mycoplasma using PCR-based
approach. They are not listed in the database of commonly misidentified cell lines.
Antibodies. The antibodies used in this paper are shown as follows. Anti-H. pylori
antibody (Abcam, ab20459) was validated and published by Rossez et al.52. Rat
Fig. 4 Gathering of integrins α5/β1, Lewisb, and sialyl Lewisx by CAG or CAG-containing OMV in the rafts region. a Integrins α5 and β1 and b Integrin β1
gathered at the rafts region by treatment of AGS cells with CAG (a) or with H. pylori 26695 OMVs (b). AGS cells were treated with CAG(18:0) for 1 h (a)
or with OMVs for 8 h (b), and then fixed. Immunofluorescent staining was then applied to indicate lipid rafts (red), integrin α5 or β1 (cyan), and nuclei
(blue). The co-localization of the first two is shown in color of fair pink. Scale bars: 20 (upper) and 5 (lower) μm. c–e Effects of integrin-blocking antibodies
on H. pylori adhesion, CagA translocation, and the related tyrosine phosphorylation. AGS cells were treated with or without the integrin α5- or β1-blocking
antibodies for 1 h, and incubated in the presence or absence of CAG(18:0) for additional 1 h, and then infected with H. pylori 26695. Adherence was
measured by flow cytometry analysis (c) as the proportion of adhered cells with H. pylori (%; shown in each plot). The quantitation made in c was
summarized in (d). Levels of CagA translocation and CagA tyrosine phosphorylation were detected by immunoblotting and shown in e. f, g Gathering of
Lewisb (f) and sialyl Lewisx (g) in the rafts region by treatment of KATO III cells with H. pylori 26695 OMVs. The procedure and staining were similar to
those of (b). Scale bars: 20 (upper) and 5 (lower) μm. h and i stand for quantitation of the confocal images made in f and g, respectively. j, k Effect of
Lewisb-blocking antibodies on H. pylori adhesion. The procedure was similar to that of c and d. In d, h, i, and k, data are provided in Supplementary Data 1
and shown as mean ± SD and all statistically significant differences are indicated with asterisks; ***p < 0.001, **p < 0.01, *p < 0.05 vs. the control group
(n= 3). Uncropped immunoblot images for e are provided in Supplementary Fig. 4.
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anti-integrin β1 clone AIIB2 (Merck, MABT409) was validated its functionally
blocking antibody by abrogating AGS cell attachment to fibronectin53. This anti-
body was validated its immunocytochemistry activity in AGS cells53. Rat anti-
integrin α5 clone BIIG2 (DSHB, AB 528155) was validated its blocking function by
Damsky and co-workers54. This antibody was validated its immunocytochemistry
activity by Fisher and co-workers55. Mouse anti-blood group Lewisb antibody
(IgM) T218 (Santa cruz, Sc-59470) was validated and published by Taniguchi
et al.56. Mouse anti-CD15s (sialyl Lewisx) that is a monoclonal antibody
unconjugated clone CSLEX1 (BD Biosciences, 551344) was validated and published
by Walz et al.57. Anti-H. pylori Cag antigen IgG fraction (monoclonal) (Austral
Biologicals, HPM-5001-5) and anti-H. pylori Cag antigen IgG fraction (polyclonal)
(Austral Biologicals, HPP-5003-9) were validated and published by Tegtmeyer
et al.25. Mouse anti-phosphotyrosine antibody, clone 4G10 (Sigma Millipore,
05-321) was validated and published by Shuai et al.58. Polyclonal rabbit anti-H.
pylori CGAT-specific antibody was created in this study and validated by com-
paring with the positive and negative controls.
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In addition, the secondary antibodies are shown as follows: Goat anti-rabbit
IgG (pre-adsorbed to 10 nm gold) (Abcam, ab27234), goat anti-rabbit IgG H&L
(HRP) (Abcam Ab6721), anti-GAPDH antibody for mAbcam 9484 loading
control (HRP) (Abcam Ab9482), goat anti-mouse IgG H&L cross-adsorbed
secondary antibody (Alexa Fluor 488) (Thermo Fisher, A-11001), goat anti-
mouse IgG (HRP) (Santa Cruz, sc-2005), goat anti-rabbit (Alexa Fluor 488)
(Invitrogen A11034), goat anti-rat IgG H&L cross-adsorbed secondary antibody
(Alexa Fluor 488) (Thermo Fisher, A-11006), and goat anti-mouse IgM CFL488
(Santa cruz, sc-395784).
Sample preparation of H. pylori cholesteryl glucosides. First, 50 μM azido-
cholesterol was added to the culture of H. pylori. Then, Folch partitioning was
performed using a chloroform/methanol (1/2) extraction for 1 h and another round
of chloroform/methanol (2/1) extraction for 1 h, followed by an extraction with
0.9% KCl. The organic layer was evaporated to give a dried residue that was then
subjected to a click reaction with 0.25 mM alkyne-dye (4-N-methylamino-1,8-
napthalimidopropyne, abbreviated as MAN) in the presence of 1.25 mM tris
(benzyltriazolylmethyl)amine (TBTA), 12.5 mM sodium ascorbate, and 0.25 mM
CuSO4 at room temperature for 1 h. After the samples were dried, they were stored
at −20 °C until HPLC or MS analysis.
Analysis of cholesteryl glucosides. These experiments were performed as pre-
viously described14. For ultrahigh-performance liquid chromatography (UPLC,
Waters)-MS (Orbitrap Elite, Thermo), a CSM C-18 column was used with a gra-
dient from 30% acetonitrile (ACN) with 20 mM ammonium acetate to a mixture of
90% isopropyl alcohol and 10% ACN with 20 mM ammonium acetate. The mass
spectrometer was operated in positive electrospray ion mode set to one full FT-MS
scan (m/z 200–1600; 15,000 resolution) and switched to different FT-MS product
ion scans (15,000 resolution) for the different precursors of cholesteryl glucoside
derivatives. Both collision-induced dissociation and higher energy collisional dis-
sociation were utilized to perform the fragmentation. For sensitive quantitation,
multiple reaction monitoring was performed, which detected the fragment of MAN
at 366.16 m/z.
Protein overexpression and purification. Plasmids were transformed into E. coli
BL21 (for CGT and CGAT) for protein overexpression. Isopropyl β-D-1-thioga-
lactopyranoside at a concentration of 0.4 mM was used to induce overexpression at
16 °C for 16–24 h. E. coli cells were harvested by centrifugation at 6000 r.p.m. with
a JLA-8.1000 rotor (Beckman). For lysis, pellets were suspended in 20 mM Tris
buffer with 200 mM NaCl and 1 mM EDTA, pH 8.0. The cells were then lysed by a
cell disruptor (Constant Systems) for 5–10 times. The lysates were centrifuged at
1500 g for 10 min to remove cell debris. Ultracentrifugation was then applied at
40,000 r.p.m. with a Type 45 Ti Rotor (Beckman) for 1 h to obtain the membrane
fraction. The pellets were stirred overnight in 20 mM Tris buffer with 200 mM
NaCl and 1% n-dodecyl-β-D-maltopyranoside at pH 8.0 and 4 °C. The resulting
mixture was applied for ultracentrifugation again to obtain the soluble membrane
proteins in the supernatant. Since all the constructs contained His-tags, a Ni-NTA
column was used to purify the target proteins. Buffers containing 0.04% DDM and
900 mM imidazole were used to elute the target proteins. Fractions from pur-
ification were analyzed by SDS-PAGE. The proteins were further concentrated by
10 kD Amicon Ultra-15 Centrifugal Filter Units (Millipore) and quantitated by a
DC™ protein assay kit (Bio-Rad). All the proteins were stored at −80 °C in the
presence of 20% glycerol.
Fig. 5 Amiodarone effectively prevented H. pylori from adhesion. a Concentration–response plots of the inhibition against the CGAT-catalyzed hydrolysis
of PE (14:0,14:0) (green) and the corresponding acyltransfer (blue). b Effect of amiodarone on the CAG formation in H. pylori. H. pylori 26695 cells were
treated with amiodarone for 2 days, followed by LC-MS analysis. c–e Effects of amiodarone on H. pylori adhesion (c, d), CagA translocation, and CagA
tyrosine phosphorylation (e). After treatment with amiodadrone, H. pylori 26695 or the mutant strain ΔCGAT was cultured with AGS cells for 1 h. Degree
of adhesion was measured by flow cytometry analysis (c) and quantitated as the proportion of adhered cells with H. pylori (%, shown in each plot). The
quantitation was summarized in (d). f–h Effects of amiodarone and OMVs on H. pylori adhesion (f, g), CagA translocation, and CagA tyrosine
phosphorylation (h). AGS cells were treated with or without amiodarone in the presence of H. pylori 26695 OMVs (or the OMVs that had been pretreated
with CAG(18:0)) for 8 h and then infected with H. pylori 26695 for another 1 h. f, g Degree of adhesion was shown in the same manner as c and d,
respectively. i CAG levels in H. pylori 26695 and ten MDR strains clinically isolated. The bacterial strains were cultured for 2 days, followed by LC-MS
analysis. j Effect of amiodarone on the CAG formation (shown by LC-MS analysis) in MDR 5024 strain. k, l Effects of amiodarone on the adhesion of MDR
5024 (k), CagA translocation, and the tyrosine phosphorylation (I). After treatment with amiodarone, MDR 5024 infected AGS cells for 1 h. In j–l, MDR+I
denoted the incubation of MDR 5024 with amiodarone. In b, d, g, j and k, all statistically significant differences are indicated with asterisks; ***p < 0.001,
**p < 0.01, *p < 0.05 vs. the control group (n= 3). In a–d, g, i–k, data are shown as mean ± SD, and provided in Supplementary Data 1. Uncropped
immunoblot images for e, h, and l are provided in Supplementary Fig. 4.
Fig. 6 Schematic presentation demonstrates how CGAT is involved in H. pylori pathogenesis. a H. pylori secretes OMVs to deliver the enzymes CGAT
and CGT to the host epithelial cells. b Upon translocation, the two enzymes produce human lipid-containing CAGs to enhance lipid raft clustering. c The
integrins and Lewis antigens then gather at the raft region, leading to great enhancement in the bacterial adhesion. Therefore, CGAT inhibitor is able to
blockade the adhesion, which sheds light on the discovery of a potentially new target to eradicate H. pylori infection.
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Cell fractionation of H. pylori. These experiments were performed as previously
described15,59–61 with some modifications. Briefly, H. pylori was growth for 2 days
and was washed with phosphate-buffered saline (PBS) for three times and re-
suspended in 50 mM HEPES and 0.2 M NaCl buffer. To lyse bacteria, sonication
was performed for 30 min alternatively repeated with sonication (10 s) and rest
(10 s). The lysed cells were centrifuged at 2000 g for 20 min to remove unlysed cells
and other large cell debris. The resulting supernatant was subjected to ultra-
centrifugation for 90 min at 82,000 g to obtain the cytoplasmic fraction (super-
natant). Pellet containing membrane fractions was further separated to give inner
and outer membrane fractions by differential solubilization with N-laur-
oylsarcosine (Sigma). Resuspension of this pellet by 500 µl of 50 mM Tris-HCl
(pH 7.5) with 0.6% (w/v) N-lauroylsarcosine was performed. After 20 min of N-
lauroylsarcosine incubation and 82,000 g ultracentrifugation for 90 min at 4 °C, the
inner membrane fraction was obtained in the supernatant. The pellet containing
outer membranes was re-suspended in 500 µl of 50 mM Tris-HCl (pH 7.5) buffer
and stored for further experiment.
OMV purification. These experiments were performed as previously described62.
H. pylori liquid cultures were harvested by centrifugation at 6000 g for 30 min. The
medium was filtered by 0.45 μm filters and then subjected to ultracentrifugation at
36,000 r.p.m. in a Type 45 Ti Rotor for 1 h. Pellets were washed with PBS and
combined. After another step of ultracentrifugation, the pellets were re-suspended
in F12 medium, and protein was quantitated by a DC™ protein assay kit. Samples
were stored at −20 °C until used. For imaging of OMVs, OMVs were stained with
Vancomycin BODIPY™ FL Conjugate (Thermo Fisher, v34850).
Activity assays of CGAT. CGAT activity was measured by MS-based determi-
nation of CAG and lysophosphatidylethanolamine. First, 10 μl of 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine (PE) (5 mM in ethanol) and 2 μl of CG-MAN
(2mM in ethanol) were evaporated. Second, buffer at a final volume of 100 μl
containing 100 mM formic acid and 10 mM EDTA was mixed with dried PE and
CG. Third, recombinant CGAT was added to the reaction buffer to a final con-
centration of 100 nM, followed by sonication of the resulting mixture for 5 s. The
reaction was incubated for 16 h before the addition of CaCl2. The resulting mixture
was further incubated for 2 h. The reaction was terminated and simply extracted by
adding 10 μl of EDTA (0.5 M) and 90 μl of KCl (0.9%) with chloroform/methanol
(1/2). The aqueous layer was then extracted again with chloroform/methanol (2/1),
and the organic layers were combined and evaporated to give dried residues that
were stored at −20 °C until MS analysis.
Protein identification. Protein samples were analyzed by SDS-PAGE. After nor-
mal staining and destaining procedures, the desirable bands were cut into small
slices and completely destained with 50% ACN in 25 mM ammonium bicarbonate
(ABC) buffer. Reduction was performed by using 50 mM dithiothreitol in 25 mM
ABC buffer at 37 °C for 1 h. The alkylation was performed by using 100 mM
iodoacetamide in 25 mM ABC buffer at room temperature for 1 h in dark. Gel
slices were then washed four times with 50% ACN in 25 mM ABC buffer for
15 min each and dried after the addition of 100% ACN. Lys-C and Trypsin in
25 mM ABC buffer were added sequentially to digest the proteins for 16 h at 37 °C.
Peptides were extracted by sonication of the gel slices in 50% ACN and 5% tri-
fluoroacetic acid for 2 min (repeatedly sonicated 10 s and relaxed 10 s) twice. After
centrifugation, the supernatants were transferred into new tubes and evaporated. A
Zip-Tip desalting procedure was then performed. After the samples had been
washed with 0.1% formic acid, they were eluted with 50% ACN and 0.1% formic
acid. The samples were then dried and subjected to proteomic analysis. Mascot
database searching was used for protein identification. The data were selected with
a false discovery rate (FDR) <1%. The searching was performed on the con-
catenated MGF files with an ion score cutoff of 50 and a significance threshold of
p < 0.05. Only peptides with ion scores over 50 were considered (bold peptide), and
only proteins with at least one unique peptide (red bold in Mascot) were con-
sidered. The mass spectrometry proteomics data have been deposited to the Pro-
teomeXchange Consortium via the PRIDE63 partner repository with the dataset
identifier PXD017518 and 10.6019/PXD017518.
Cryo-TEM imaging. Holey carbon film-covered 300 mesh copper grids (HC300-Cu,
PELCO) were glow-discharged in an (Ar, O2)-atmosphere for 10 s on the carbon
side. Samples (1–10mgml−1) of 4 μl volumes were pipetted onto grids. Grids were
blotted in 100% humidity at 4 °C for 3 s and plunge-frozen into liquid ethane cooled
by liquid nitrogen using a Vitrobot (FEI, Hillsboro, OR). Liquid nitrogen was used to
store grids. Grids were then transferred to the electron microscope using a cryostage.
Images of OMVs within the holes in the carbon film were obtained by using a Tecnai
F20 electron microscope (FEI) at 200 keV with a 70 μm objective aperture. For each
exposure, the low dose condition was ~20e−Å−2. Images were taken at 5k or 50k
magnification and 2–3 μm defocus and recorded on a 4k × 4k CCD camera
(Gatan, USA).
Cell preparation procedure. AGS cells (5 × 105) or KATO III cells (106) were
seeded onto 35 mm dishes in Dulbecco’s modified Eagle's medium (Gibco, Invi-
trogen) at 37 °C for 16 h. Cells were first washed with PBS three times before being
treated with 5 mM methyl-β-cyclodextrin in serum-free Ham’s F-12 nutrient
medium (F12 meidum) for 1 h. After washes with PBS, cells were collected for
further experiments.
Immunofluorescence microscopy. For lipid raft staining, AGS cells were sub-
jected to the cell preparation procedure and incubated with compounds for 1 h;
enzymes for 8 h; OMVs from different H. pylori strains for 1, 2, 6, or 8 h; or
different amounts of OMVs for 6 h. Lipid rafts (GM1) in AGS cells were then
labeled with Alexa Fluor 594-conjugated cholera toxin subunit β. Fluorescence
microscopy was performed to visualize the clustering of GM1. For CGAT staining,
AGS cells were subjected to the cell preparation procedure and treated with OMVs
or co-cultured with H. pylori at a multiplicity of infection (MOI) of 50 for 8 h. Cells
were then fixed (2% formaldehyde) and stained with a specific antibody for CGAT
(1:500). Immunofluorescence microscopy was performed to visualize CGAT (Alexa
Fluor 488, green). Nuclei were counterstained with DAPI (blue). For integrin or
Lewis antigen staining, AGS or KATO III cells were subjected to the cell pre-
paration procedure and treated with CAG(18:0) for 1 h or OMVs for 8 h. Lipid
rafts (GM1) in cells were then labeled with Alexa Fluor 594-conjugated cholera
toxin subunit β for 10 min. Cells were then fixed (2% formaldehyde) and stained
with a specific antibody for integrin α5 (BIIG2; 1:125) or β1 (AIIB2; 1:400) or
Lewisb antibody (T218; 1:100) or sialyl Lewisx antibody (CSLEX1; 1:1000) at 4 °C
for 16 h. Immunofluorescence microscopy was performed to visualize integrins and
Lewis antigens (Alexa Fluor 488, green).
Live-cell imaging of AGS cells. AGS cells were subjected to the cell preparation
procedure and incubated with Alexa Fluor 594-conjugated cholera toxin subunit β
(Molecular Probes, USA) for 10 min, washed with PBS three times, and then
treated with 200 μg of OMVs that had been labeled by Bodipy FL-vancomycin
(1 μM; Green fluorescence) at 37 °C for 8 h. The images of serial optical sec-
tions (1024 × 1024 pixels) were obtained under a ×100 Plan-NEOFLUAR lens
(laser 543 nm) at 5 min intervals using a Zeiss LSM 510 confocal microscope. The
shown live-cell images were representative of three independent experiments.
Immunoprecipitation and blotting. These experiments were performed as pre-
viously described14. AGS cells (6 × 105) were seeded in a six-well tissue culture dish
in Dulbecco’s modified Eagle's medium (Gibco, Invitrogen) and incubated at 37 °C
for 16 h. These cells were then treated with 5 mM methyl-β-cyclodextrin in serum-
free medium for 1 h and subsequently treated with compounds for 1 h, enzymes for
8 h, or OMVs from different H. pylori strains for 8 h. These cells were infected with
H. pylori 26695 at an MOI of 50 at 37 °C for 1 h. CagA translocation and CagA
tyrosine phosphorylation were detected by immunoblotting. After infection of AGS
cells with H. pylori, cells were washed three times with PBS and collected with a cell
scraper. To detect the CagA internalized into AGS cells, saponin was used to lyse
AGS cells while keeping the bacteria intact. The AGS cells were gently lysed with
PBS containing 0.1% saponin, protease inhibitor cocktail (Calbiochem, USA), and
phosphatase inhibitor cocktail (Calbiochem, USA) for 10 min at room temperature.
The cell debris and intact bacteria were separated from the soluble fraction by
centrifugation (6000 g for 5 min), and the solute was filtered with a 0.22-μm-pore
filter to yield human cell proteins and the internalized CagA. The saponin lysis
procedure was also performed on H. pylori 26695 alone to make sure that this
procedure did not release cytoplasmic proteins from H. pylori. Filtrate (100 μg) was
immunoprecipitated by using 10 μg of rabbit anti-CagA polyclonal antibody
(Austral Biologicals, USA) and 30 μl of Protein A Plus Agarose (Thermo Scientific,
USA) at 4 °C overnight. The obtained precipitates were washed three times with
immunoprecipitation buffer (25 mM Tris, 150 mM NaCl, 5 mM EDTA, and 1%
TX-100, pH 7.4) and once with TBS buffer (50 mM Tris, 150 mM NaCl, and 1 mM
CaCl2, pH 7.4) and boiled in SDS-PAGE sample buffer (62.5 mM Tris, 2% SDS,
10% (v/v) glycerol, and 0.05% brilliant blue R, pH 6.8) at 95 °C for 10 min. The
resulting samples were resolved by 6% SDS-PAGE, and the bands were transferred
onto polyvinylidene difluoride membranes (Millipore, USA). The membranes were
blocked with 5% (w/v) BSA in TBS buffer containing 0.01% Tw-20 at room
temperature for 1 h and incubated overnight with mouse monoclonal anti-CagA
(Austral Biologicals; 1:2000), mouse monoclonal anti-phosphotyrosine (4G10,
Millipore; 1:2000) or mouse monoclonal anti-GAPDH (ab9482, Abcam, UK;
1:5000) at 4 °C. The blots were washed and incubated with HRP-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology, USA) at a 1:5000 dilution, and the
proteins of interest were visualized using an enhanced chemiluminescence assay
(WBKLS0500, Millipore).
Flow cytometry analysis. Cells treated with compounds, enzymes, OMVs,
blocking antibodies, or inhibitors were infected with H. pylori 26695 (MOI= 50) at
37 °C for 1 h. After the cells were washed to remove non-adherent bacteria, they
were detached with 2 mM EDTA and fixed with 2% formaldehyde. Cells with
plasma membrane-associated H. pylori bacteria were stained with rabbit anti-H.
pylori antibody (Abcam, 1:1,000) at 4 °C for 16 h and then washed with PBS. The
secondary antibody was fluorescein isothiocyanate (FITC)-conjugated goat anti-
rabbit antibody (Invitrogen, 1:1000), which was applied at 4 °C for 1 h, and the
samples were then washed with PBS. Cells were analyzed by a flow cytometry
system (BD FACSCalibur Calibur Flow Cytometer 4 Color). BD FACStation
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Software (Version 3.3) was used for the data acquisition. Adherence was quanti-
tated in terms of the proportion of cells with adherent H. pylori. At least over
10,000 cells were collected. For gating strategy, as shown in Supplementary
Fig. 5, cell debris was first removed by gating the main cell population using the
FSC/SSC gating. Mock-treated cells (cells only without bacterial infection) that had
been treated with the same staining procedure as aforementioned were used to
distinguish the boundary between the positive or negative staining populations. An
identical threshold was applied for all samples within the same cell line.
Statistics and reproducibility. The results are expressed as the mean ± SD
(standard deviation). For the graphs, data were combined from at least three
biological independent experiments. Statistical significance between two samples
was tested by an unpaired t-test using Prism 8.0 software (GraphPad Software, La
Jolla, CA). All statistically significant differences are indicated with asterisks;
***p < 0.001, **p < 0.01, *p < 0.05 (not significant, p > 0.05).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The data that support the findings of this study are available from the corresponding
author on request. All source data in the main figures are available in Supplementary
Data 1 and 2. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE63 partner repository with the dataset
identifier PXD017518 and 10.6019/PXD017518. Full blots are shown in Supplementary
Information.
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